drugset / Trial / NCT02372305

Comparison of FlexHD and Alloderm Outcomes in Breast Reconstructive Surgery

NCT02372305

Phase 4 Withdrawn University of Arkansas
RandomizedParallel-groupOpen-labelTreatment

Summary

FlexHD and Alloderm are two common products used in breast reconstruction to hold tissue expanders and implants in place. There have been few chart review studies comparing outcomes between the two materials in breast reconstruction. These studies have determined there is no difference in complication rates between the two materials. However, there have never been any active studies to date. This study will serve as a randomized controlled trial comparing FlexHD and Alloderm. Several outcomes will be measured based off of inclusion and exclusion criteria to determine if either product is more suitable for use in breast reconstruction. This will be performed by randomly assigning patients to receive either FlexHD or Alloderm. Designated outcomes will be followed closely postoperatively. Outcomes will be statistically analyzed to determine complication rates between FlexHD and Alloderm and thus which product is better to use in breast reconstruction.

Timeline

Start
2016-03
Primary completion
2017-12-21
Completion
2017-12-21

Drugs

EvaluationDrugModalityDoseRoute
Comparator AlloDerm Other / unclassified
Comparator FlexHD Unknown

Indications